The FDA has granted approval for ustekinumab (Stelara/Janssen Biotech) to treat adults with moderately-to severely active Crohn’s disease (CD).
Panelists Peter L. Salgo, MD, and Joshua D. Lee, MD, PhD, discuss patient selection criteria for the use of long-acting naltrexone in the treatment of individuals with opioid dependency.
Peter L. Salgo, MD; Joshua D. Lee, MD, PhD; and Phillip Barbour discuss the mechanism of action for methadone and buprenorphine to prevent relapse in those who have a history of substance abuse.
Sirukumab, a rheumatoid arthritis treatment that has performed well in recent studies, is now awaiting approval in both the United States and Europe.
The FDA today approved its fourth biosimilar, a tumor necrosis factor inhibitor similar to adalimumab.
Peter A. McCullough, MD, and Nicolaas Deutz, MD, PhD, highlight the role of amino acids, protein, and B-hydroxy B-methylbutyrate in rebuilding muscle mass for patients with sarcopenia.
Nicolaas Deutz, MD, PhD, and Peter A. McCullough, MD, discuss the importance of the role of protein in treating malnutrition and sarcopenia.
Using older mice, researchers looking for ways to prevent stroke found a protective effect in bexaratone. The age of the mice is significant in that most studies are done on young animals and findings might not apply to mice that have aged.
Peter Salgo, MD; Milton Packer, MD; Scott Solomon, MD; and John R. Teerlink, MD, remark on the appropriateness and benefits of treating patients with heart failure with an angiotensin receptor/neprilysin inhibitor (ARNI) (ie, valsartan/sacubitril) rather than with an angiotensin-converting enzyme (ACE) inhibitor.